Key points are not available for this paper at this time.
cleavage and polyadenylation specificity factor (CPSF3) endonuclease. As a result of these studies and its promising profile, DNDI-6148 has been declared a preclinical candidate for the treatment of VL.
Mowbray et al. (Fri,) studied this question.